Novo Nordisk A/S Release: Transaction in Own Shares

December 1, 2009 |

1 min read

BAGSVÆRD, DENMARK--(Marketwire - December 01, 2009) - Status regarding Novo Nordisk’s holding of own shares

In continuation of the company’s announcement dated 7 August 2009 concerning Novo Nordisk’s share repurchase programme, and pursuant to Section 29 of the Danish Securities Trading Act, this is to report that as of today, Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates own more than 5% of the total share capital in Novo Nordisk A/S.

As per 1 December 2009, Novo Nordisk A/S and its wholly-owned affiliates own 31,063,977 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 31,063,977 or 5.0% of the total share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.

Company Announcement no 71 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.